---
title: "Invizyne Tech (IZTC.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/IZTC.US.md"
symbol: "IZTC.US"
name: "Invizyne Tech"
industry: "生物技术"
---

# Invizyne Tech (IZTC.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |

## Company Profile

Invizyne Technologies, Inc. 是一家在美国运营的合成生化公司。该公司开发了 SimplePath，一个生产化学品的平台，包括药品、燃料、材料、食品添加剂和新型化合物。其平台还包括一个或多个模块，这些模块由一个或多个酶组成，这些酶协同工作以执行特定的生物催化转化

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-01T04:30:13.000Z

**Overall: D (0.78)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 352 / 406 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.70% |  |
| Net Profit YoY | -284.77% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | -700.00 |  |


**Multi Score**: D

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 342.26% | A |
| Profit Margin | 731989.29% | A |
| Gross Margin | 0.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.70% | E |
| Net Profit YoY | -284.77% | E |
| Total Assets YoY | 3.95% | C |
| Net Assets YoY | -693.16% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 0.01% | C |
| OCF YoY | -100.70% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 201.15% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Invizyne Tech",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "342.26%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "731989.29%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.70%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-284.77%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.95%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-693.16%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "0.01%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-100.70%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "201.15%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | MiMedx (US.MDXG) | A | B | A | B | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/IZTC.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/IZTC.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/IZTC.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.